← Back to Search

Device

CardioMEMS™ HF System for Heart Failure (GUIDE-HF Trial)

N/A
Waitlist Available
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6, and 12 months post-implantation
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a heart monitoring device called the CardioMEMS™ HF System in patients with severe heart failure symptoms or a history of hospitalizations. The device helps doctors track heart pressure and manage treatment to prevent future heart issues. CardioMEMS is a wireless pulmonary artery pressure monitoring device that has shown efficacy in reducing heart failure hospitalizations.

Eligible Conditions
  • Heart Failure
  • Congestive Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6, and 12 months post-implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6, and 12 months post-implantation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
(Randomized Arm) Composite outcome of (1) HFHs, (2) intravenous diuretic visits, and (3) all-cause mortality
(Single Arm) Composite outcome of (1) HFHs, (2) intravenous diuretic visits, and (3) all-cause mortality
Secondary study objectives
Upper arm
(Randomized Arm) All-cause mortality
(Randomized Arm) Composite outcome of (1) HFHs and (2) intravenous diuretic visits
+11 more
Other study objectives
(Randomized Arm) All-cause hospitalizations
(Randomized Arm) Cardiovascular mortality
(Randomized Arm) Frequency of clinician review of subject PA pressure uploads
+15 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Group II: Randomized Arm - Treatment GroupExperimental Treatment1 Intervention
Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Group III: Randomized Arm - Control GroupExperimental Treatment1 Intervention
Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CardioMEMS™ HF System
2018
N/A
~2360

Find a Location

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
650 Previous Clinical Trials
408,988 Total Patients Enrolled
126 Trials studying Heart Failure
50,393 Patients Enrolled for Heart Failure
Poornima Sood, MD, MBAStudy DirectorAbbott
7 Previous Clinical Trials
2,379 Total Patients Enrolled
6 Trials studying Heart Failure
2,370 Patients Enrolled for Heart Failure
Nessa Johnson, PhDStudy DirectorAbbott
~311 spots leftby Nov 2025